KINIKSA PHARMACEUTICALS, LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.77 USD | -1.69% |
|
+1.23% | +12.71% |
| May. 14 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
| Apr. 23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 389M | Sales 2025 * | 536M | Capitalization | 1.4B |
|---|---|---|---|---|---|
| Net income 2024 * | -7M | Net income 2025 * | 42M | EV / Sales 2024 * | 2.98 x |
| Net cash position 2024 * | 242M | Net cash position 2025 * | 386M | EV / Sales 2025 * | 1.89 x |
| P/E ratio 2024 * |
-186
x | P/E ratio 2025 * |
33.9
x | Employees | 297 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kiniksa Pharmaceuticals, Ltd.
More recommendations
More press releases
| 1 day | -1.69% | ||
| 1 week | +1.23% | ||
| Current month | +5.61% | ||
| 1 month | +17.12% | ||
| 3 months | -0.85% | ||
| 6 months | +25.84% | ||
| Current year | +12.71% |
1 week
19.38
20.27
1 month
16.8720.52
Current year
16.5622.09
1 year
13.3722.09
3 years
7.3622.09
5 years
5.0128.67
10 years
5.0132.88
| Managers | Title | Age | Since |
|---|---|---|---|
Eben Tessari
FOU | Founder | 42 | 15-06-30 |
Sanj Patel
CEO | Chief Executive Officer | 54 | 15-06-30 |
Mark Ragosa
DFI | Director of Finance/CFO | 50 | 18-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 15-09-30 |
Barry Quart
BRD | Director/Board Member | 67 | 15-09-30 |
Thomas Malley
BRD | Director/Board Member | 55 | 16-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% | ||
| 0.05% | 0 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 19.77 | -1.69% | 257,669 |
| 24-05-16 | 20.11 | +0.05% | 303,615 |
| 24-05-15 | 20.1 | +3.18% | 254,963 |
| 24-05-14 | 19.48 | -0.51% | 205,113 |
| 24-05-13 | 19.58 | +0.26% | 193,968 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
19.77
USD
Average target price
30.67
USD
Spread / Average Target
+55.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.71% | 1.4B | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- KNSA Stock
